phenothiazin
deriv
test
inhibit
sarscov
replic
phenothiazin
slightli
inhibit
sarscov
replic
neutral
red
nr
uptak
assay
ad
propylamino
group
give
promazin
reduc
viru
yield
vyr
assay
ec
without
select
variou
substitut
basic
phenothiazin
structur
promot
efficaci
phenazin
ethosulf
potent
compound
vyr
assay
ec
compound
toxic
ic
except
phenoxathiin
ic
alphadiethylaminopropionyl
ic
consequ
none
select
inhibitor
sarscov
replic
si
valu
data
portend
poor
efficaci
promazin
sarscov
mous
lung
replic
model
intraperiton
treatment
promazin
use
prophylact
h
therapeut
regimen
mg
kg
day
reduc
viru
lung
titer
day
yet
prolong
viru
replic
day
similar
therapeut
promazin
dose
efficaci
thu
promazin
affect
sarscov
replic
vitro
vivo
phenothiazin
efficaci
reduc
viru
replic
therefor
treat
sar
infect
compound
like
promazin
warrant
sever
acut
respiratori
syndrom
sar
emerg
guandong
provinc
southern
china
new
infecti
respiratori
diseas
character
influenzalik
symptom
sign
high
mortal
rate
initi
outbreak
sar
infect
rapidli
spread
human
popul
due
intern
travel
reach
nearli
countri
middl
de
clercq
episod
possibl
portent
epidem
futur
overal
mortal
rate
within
elderli
popul
de
clercq
epidem
result
probabl
case
sar
death
attribut
viru
infect
also
four
confirm
case
sar
ghangzou
china
late
earli
liang
et
al
song
et
al
two
subsequ
outbreak
contain
rapidli
due
escap
viru
laboratori
sarscov
research
lim
et
al
sar
appear
lifethreaten
highli
contagi
resourc
scienc
commun
quickli
marshal
gain
better
understand
diseas
etiolog
agent
facilit
develop
ration
therapi
prophylaxi
treatment
weiss
navasmartin
de
clercq
thu
put
agent
quickli
identifi
coronalik
viru
soon
shown
etiolog
agent
sar
fouchier
et
al
earli
sar
outbreak
concert
effort
mani
laboratori
evalu
clinic
approv
drug
efficaci
sarscovto
rapidli
provid
treatment
sar
infect
human
exampl
sever
laboratori
evalu
phenothiazin
promazin
clinic
approv
antipsychot
drug
mani
deriv
two
class
compound
inhibit
sarscov
replic
zhang
yap
barnard
et
al
hsieh
et
al
posit
data
prompt
recommend
type
drug
consid
therapi
sar
infect
lead
compound
develop
potent
deriv
data
present
confirm
extend
vitro
antisarscov
efficaci
previous
report
show
vivo
model
clinic
use
contraind
african
green
monkey
kidney
cell
vero
obtain
american
type
cultur
collect
atcc
manassa
va
cell
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
hyclon
laboratori
logan
ut
antivir
assay
serum
reduc
gentamicin
ad
medium
sarscov
strain
urbani
obtain
center
diseas
control
atlanta
ga
frankfurt
strain
kindli
provid
jindrich
cinatl
klinikum
der
jw
goeth
frankfurt
main
germani
strain
suppli
heinz
feldman
nation
microbiolog
laboratori
winnipeg
manitoba
canada
strain
receiv
paul
ks
chan
chines
univers
hong
kong
china
strain
passag
vero
cell
experi
involv
infecti
sarscov
carri
laboratori
personnel
wore
complet
bodi
protect
cover
hepafilt
power
air
purifi
respir
promazin
phenoxathiin
chlorprothixen
phenoxazin
phenothiazin
perphenazin
ethopropazin
methotrimeprazin
acetopromazin
obtain
sigmaaldrich
co
st
loui
mo
mp
biomed
irvin
ca
trifluoperazin
dimal
obtain
calbiochem
la
jolla
ca
acetophenazin
maleat
receiv
uspc
inc
rockland
md
solubil
physiolog
salin
pss
dimethylsulphoxid
dmso
chlorprothixen
phenoxazin
phenothiazin
dilut
pss
work
concentr
refer
drug
vitro
efficaci
test
calpain
inhibitor
iv
calbiochem
mous
interferonalpha
refer
drug
anim
studi
provid
kurt
berg
panum
inst
immi
ifnlab
copenhagen
denmark
compound
test
vari
concentr
four
log
eight
log
dilut
viru
compound
ad
equal
volum
nearconflu
cell
monolay
tissu
cultur
plate
multipl
infect
rang
order
produc
viral
cytopath
effect
cpe
strain
viru
cell
viru
control
well
within
day
plate
incub
co
atmospher
cell
viru
control
well
show
complet
viral
cpe
observ
light
microscopi
concentr
drug
assay
viru
inhibit
triplic
cytotox
duplic
six
well
per
plate
set
asid
uninfect
untreat
cell
control
six
well
per
plate
receiv
viru
repres
control
viru
replic
calpain
inhibitor
iv
includ
posit
control
drug
set
compound
test
examin
virusinfect
control
light
microscopi
viral
cpe
cpe
compound
cytotox
quantit
nr
assay
nr
assay
perform
use
method
cavenaugh
et
al
modifi
barnard
et
al
briefli
medium
remov
well
plate
nr
ad
test
medium
well
plate
plate
incub
h
dark
solut
remov
well
rins
remain
dye
extract
use
ethanol
buffer
citrat
buffer
absorb
nm
read
micropl
reader
opsi
dynex
technolog
chantilli
va
absorb
valu
express
percent
untreat
control
ec
ic
si
valu
calcul
describ
previous
barnard
et
al
compound
evalu
sensit
assay
confirm
result
cpe
inhibitionnr
uptak
assay
infecti
viru
yield
well
second
cpe
inhibit
assay
determin
previous
describ
barnard
et
al
cpe
determin
plate
frozen
thaw
sampl
well
concentr
test
pool
titer
vero
cell
infecti
viru
cpe
assay
reduct
viru
yield
calcul
linear
regress
analysi
repres
one
log
inhibit
titer
compar
untreat
viru
control
compound
show
good
antivir
inhibitori
activ
virucid
test
done
exclud
possibl
compound
inhibit
viru
physic
inactiv
disrupt
virion
method
barnard
et
al
use
viru
compound
incub
room
temperatur
h
surviv
viru
quantifi
cpe
assay
titer
calcul
describ
previous
barnard
et
al
concentr
compound
test
bracket
concentr
determin
repres
ec
previou
assay
concentr
test
compound
assay
duplic
anim
studi
animalsspecif
pathogenfre
balbc
femal
mice
g
rang
vari
experi
obtain
charl
river
laboratori
wilmington
quarantin
week
prior
use
mice
fed
standard
mous
chow
tap
water
ad
libitum
mous
studi
approv
utah
state
univers
anim
care
use
committe
carri
approv
biosafeti
level
facil
personnel
enter
facil
wore
power
airpurifi
respir
hepa
airmat
saint
paul
mn
infecti
diseas
experi
mice
hous
bonnet
filtertop
cage
place
within
hepafilt
horizont
laminar
flow
ventil
anim
rack
lung
viru
titer
determinationseach
mous
lung
homogen
vari
dilut
assay
infecti
viru
vero
cell
lung
homogen
store
supernat
fluid
titer
cpe
assay
experi
designin
one
set
experi
twenti
mice
per
group
treat
intraperiton
ip
inject
appropri
dosag
compound
placebo
salin
administ
h
prior
infect
mice
h
pretreat
mice
sedat
ip
inject
mgkg
infect
intranas
clarifi
viru
lysat
cell
cultur
infecti
dose
strain
urbani
treatment
continu
h
viru
exposur
uninfect
anim
three
dose
compound
placebo
treat
dosag
drug
placebo
serv
toxic
control
fifteen
anim
placebotr
drugtreat
infect
group
sacrif
day
postviru
exposur
lung
remov
assay
viru
remain
mice
sacrif
day
lung
remov
weigh
titer
viru
experi
repeat
use
mgkg
dose
addit
anim
sacrif
day
lung
sampl
taken
day
sacrif
anim
cytokin
analysi
titrat
viru
lung
homogen
anoth
set
experi
promazin
evalu
therapeut
efficaci
prior
infect
viru
mice
sedat
ip
inject
mgkg
infect
intranas
clarifi
viru
lysat
describ
ten
mice
per
group
treat
ip
promazin
mgkg
anim
given
placebo
salin
administ
one
time
h
postviru
exposur
inject
h
viru
exposur
qd
uninfect
anim
three
dose
compound
placebo
treat
dose
drug
placebo
serv
toxic
control
ten
anim
placebotr
seven
anim
drugtreat
infect
group
sacrif
day
postviru
exposur
lung
remov
assay
viru
remain
mice
sacrif
day
lung
remov
weigh
titer
viru
histopathologylung
section
fix
formalin
ship
utah
state
veterinari
diagnost
laboratori
logan
ut
process
section
hematoxylin
eosin
stain
descript
analysi
cytokin
analysislung
sampl
taken
day
postviru
exposur
homogen
mem
fb
sampl
held
frozen
thaw
equilibr
mgml
sampl
test
gmcsf
rant
use
mous
cytokin
array
screen
quansi
bioscienc
logan
ut
cytokin
screen
quantit
elisabas
test
distinct
captur
antibodi
absorb
well
plate
defin
array
cytokin
detect
quantifi
rel
luminesc
spot
array
valu
pgml
calcul
use
softwar
develop
quansi
base
standard
curv
run
concurr
assay
statist
analysisdiffer
mean
lung
viru
titer
evalu
analysi
varianc
cytokin
level
analysi
wilcoxon
pairwis
comparison
test
group
done
use
jmp
statist
sa
cari
nc
number
phenazin
phenothiazin
test
efficaci
sarscov
urbani
strain
replic
vero
cell
tabl
ec
valu
rang
phenoxathiin
phenazin
ethosulf
nr
assay
compound
exhibit
consider
toxic
except
phenoxathiin
alphadiethylaminopropionyl
potent
inhibitor
viru
yield
reduct
assay
phenazin
ethosulf
ec
promazin
compound
report
inhibit
sarscov
zhang
yap
hsieh
et
al
also
reduc
viru
yield
ec
addit
promazin
also
inhibit
strain
sarscov
similar
concentr
tabl
detect
nr
assay
viru
yield
reduct
assay
compound
test
sarscov
strain
also
inhibitori
similar
concentr
use
either
assay
except
phenothiazinehcl
antivir
activ
shown
tabl
due
virucid
activ
least
promazin
sinc
viru
exposur
promazin
h
result
viru
titer
reduct
data
shown
least
toxic
compound
evalu
phenoxathiin
ic
phenoxazin
essenti
inact
sinc
concentr
cytotox
effect
detect
cell
less
concentr
detect
inhibit
viru
replic
proteas
inhibitor
calpain
iv
posit
drug
control
inhibit
viru
replic
expect
barnard
et
al
structureact
relationship
could
establish
data
fig
b
phenothiazin
moder
inhibit
sarscov
replic
vero
cell
neutral
red
nr
uptak
assay
ec
addit
propylamino
group
phenothiazin
give
promazin
result
twofold
increas
inhibit
sarscov
replic
nr
assay
ec
ec
fig
addit
deriv
phenothiazin
side
chain
enhanc
solubl
side
chain
electron
withdraw
ring
structur
trifluoperazin
acetophenazin
perphenazin
also
inhibitori
sarscov
replic
ec
suggest
compound
may
act
solubl
prodrug
phenothiazin
fig
effect
seem
abrog
methoxi
acetyl
propionyl
group
ad
two
posit
basic
ring
structur
substitut
n
phenothiazin
nucleu
get
phenoxathiin
result
much
less
potent
much
less
toxic
compound
phenoxathiin
ec
vs
ec
phenothiazin
howev
substitut
group
phenothiazin
result
less
potent
compound
phenoxazin
also
less
toxic
nitrogen
phenothiazin
basic
ring
structur
may
essenti
antivir
activ
sinc
remov
ring
exampl
chlorprothixen
result
inhibit
viru
replic
similar
detect
promazin
treatment
mice
promazin
mg
kg
day
h
h
viru
exposur
result
signific
reduct
viral
replic
day
tabl
lung
mice
durat
viru
replic
lung
significantli
prolong
drug
treatment
h
h
viru
exposur
viru
detect
mice
treat
mgkg
mgkg
promazin
day
day
contrast
placebotr
infect
mice
infect
lung
clear
day
previous
shown
other
barnard
et
al
despit
fact
viru
persist
day
promazinetr
mice
histopathog
examin
lung
treat
infect
anim
show
sign
patholog
consist
viru
lung
infect
consist
druginduc
cytotox
treat
mice
mg
kg
day
promazin
h
h
viru
exposur
lethal
mice
day
tabl
refer
report
ld
promazin
given
mice
ip
mg
kg
day
yen
day
mice
also
treat
therapeut
promazin
treatment
mice
promazin
mg
kg
day
begin
h
viru
exposur
somewhat
lethal
well
anim
die
day
day
tabl
dose
promazin
use
therapeut
inhibit
viru
replic
lung
although
mgkg
dose
administ
day
either
one
time
three
time
begin
h
viru
exposur
seem
slightli
increas
amount
viru
recov
lung
day
compar
placebo
neither
mgkg
dose
significantli
prolong
viru
infect
happen
frequent
dose
schedul
mgkg
dose
kill
control
anim
well
infect
treat
anim
day
sarscov
infect
placebotr
uninfect
mice
caus
signific
increas
p
product
cytokin
gmcsf
rant
compar
untreat
infect
mice
fig
uninfect
mice
promazin
treatment
alon
caus
signific
increas
p
p
mgkg
dose
tnfalpha
mgkg
dose
mgkg
dose
rant
gmcsf
compar
uninfect
untreat
mice
interestingli
promazin
administ
infect
mice
mg
kg
seem
promot
much
higher
level
detect
untreat
infect
mice
uninfect
mice
treat
promazin
infect
anim
treat
mgkg
promazin
rant
titer
significantli
lower
p
lung
untreat
infect
mice
promazin
treatment
infect
mice
significantli
affect
cytokin
level
compar
untreat
infect
mice
cytokin
level
lung
sampl
mice
sacrif
day
postinfect
significantli
differ
compar
treat
infect
mice
untreat
infect
mice
data
shown
day
detect
increas
cytokin
level
regardless
treatment
data
shown
review
antivir
therapi
sarscov
cinatl
et
al
suggest
promazin
warrant
investig
potenti
treatment
sarscov
infect
base
studi
zhang
yap
barnard
et
al
hsieh
et
al
howev
studi
present
vitro
assay
repeat
four
time
use
independ
experi
confirm
ec
ic
valu
unlik
data
report
studi
unabl
show
convinc
antivir
data
promazin
relat
compound
abl
show
efficaci
promazin
anim
model
fact
like
cytotox
properti
compound
account
slight
vitro
inhibit
viru
detect
current
studi
howev
altern
explan
slight
inhibitori
activ
phenothiazin
might
inhibit
sarscov
main
proteas
three
phenazin
predict
inhibitor
sarscov
main
proteas
dock
predict
virtual
screen
compound
actual
evalu
enzymat
assay
three
phenothiazin
inhibit
enzym
activ
addit
promazin
phenothiazin
might
also
inhibit
sarscov
main
proteas
zhang
yap
comput
studi
shown
promazin
bind
amino
acid
residu
domain
proteas
howev
bind
affin
would
probabl
suffici
caus
effect
inhibit
enzym
observ
promazin
promot
induct
certain
proinflammatori
cytokin
schizophren
may
actual
account
prolong
viru
infect
mice
observ
current
studi
mice
pretreat
promazin
treatment
schizophren
promazin
seem
induc
proinflammatori
cytokin
turn
stimul
highli
reactiv
oxygen
speci
ro
kaminska
et
al
induct
proinflammatori
cytokin
also
occur
mani
viral
respiratori
infect
includ
sar
barnard
et
al
glass
et
al
found
sarscov
infect
mice
character
proinflammatori
cytokin
storm
includ
induct
found
ribavirin
exacerb
sarscovinduc
cytokin
storm
lead
prolong
viral
replic
lung
infect
anim
barnard
et
al
addit
promazin
mg
kg
day
seem
significantli
decreas
rant
express
import
chemokin
promot
neutrophil
migrat
sarscov
infect
site
yen
et
al
promazin
suppress
rant
level
might
allow
viru
persist
lack
good
robust
neutrophil
respons
initi
infect
thu
lowdos
promazin
treatment
mg
kg
day
use
current
studi
may
alter
sarscovperturb
cytokin
level
result
prolong
infect
suppress
key
chemokin
necessari
clearanc
viru
day
lead
persist
viru
infect
howev
exacerb
infect
may
depend
frequenc
time
treatment
administr
less
frequent
dose
without
pretreat
viru
exposur
result
prolong
viru
infect
reduct
viru
lung
titer
rant
express
unaffect
lower
dose
promazin
summari
number
phenothiazin
weakli
inhibit
replic
four
strain
sarscov
vero
cell
although
activ
probabl
due
cytotox
compound
test
one
phenothiazin
promazin
evalu
sarscov
replic
model
mice
toxic
manifest
highest
dose
promazin
treatment
administ
ip
mg
kg
day
result
death
anim
treat
regardless
dose
schedul
regimen
observ
valid
signific
toxic
detect
vitro
mani
phenothiazin
evalu
vitro
even
though
twofold
lower
dose
promazin
much
less
toxic
mice
viru
lung
titer
reduc
lower
dose
promazin
mg
kg
day
administ
frequent
prior
viru
exposur
significantli
prolong
infect
given
almost
total
lack
inhibit
viru
replic
mice
except
one
dose
narrow
concentr
window
lethal
surviv
potenti
prolong
viru
infect
anim
promazin
prodrug
consid
potenti
therapi
sar
infect
cytokin
level
detect
lung
uninfect
infect
mice
without
promazin
treatment
day
postviru
exposur
data
repres
cytokin
level
lung
individu
mice
bar
indic
averag
cytokin
level
treatment
group
p
p
effect
ip
promazin
treatment
replic
sarscov
urbani
mice
dosageinject
toxic
control
survivortot
viru
titer
log
ccid
g
sd
b
viru
titer
log
ccid
g
sd
mgkg
c
mgkg
mgkg
mgkg
nd
effect
therapeut
ip
promazin
treatment
replic
sarscov
urbani
mice
dosageinject
toxic
control
survivortot
viru
titer
log
ccid
g
sd
qd
begin
h
viru
exposur
mgkg
mgkg
b
mgkg
qd
begin
h
viru
exposur
iu
c
anim
infect
treat
toxic
group
die
day
b
repres
titer
limit
detect
assay
c
interferon
administ
h
prior
viru
exposur
